Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00616577 |
|
Recruitment Status :
Terminated
(PI is no longer here.)
First Posted : February 15, 2008
Results First Posted : April 8, 2015
Last Update Posted : April 25, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Caudal epidural analgesia (caudal block) is used in standard pediatric anesthesia practice. It has been shown to be effective in managing postoperative pain in children undergoing abdominal and infraumbilical surgery (Tobias et al 1994). Furthermore, studies have shown that children receiving caudal blocks have secondary benefits such as lower narcotic and anesthetic requirements, more rapid awakening from general anesthesia, decreased time to discharge home, and fewer pain-related behaviors postoperatively (Conroy et al 1993, Tobias et al 1995, Tobias 1996).
This proposed study involves the use of a caudal block in children undergoing elective inguinal herniorrhaphy or orchiopexy to evaluate the role of preemptive analgesia in pediatric pain management. We hypothesize that by inhibiting peripheral pain receptors with a caudal block before the onset of a painful stimulus, we can decrease central nervous system sensitization and reduce postoperative analgesic requirements.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Inguinal Herniorrhaphy Orchiopexy | Drug: Ropivacaine | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 26 participants |
| Allocation: | Randomized |
| Intervention Model: | Factorial Assignment |
| Masking: | Double (Participant, Care Provider) |
| Primary Purpose: | Treatment |
| Official Title: | Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine: A Prospective, Randomized, Double-blinded, Controlled Study |
| Study Start Date : | October 2007 |
| Actual Primary Completion Date : | September 2010 |
| Actual Study Completion Date : | September 2010 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group CB
Subjects in this arm will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after induction of general anesthesia prior to surgical incision.
|
Drug: Ropivacaine
caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine |
|
Active Comparator: Group CA
Group CA (Caudal After-control group) will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after completion of surgery but before emergence from anesthesia.
|
Drug: Ropivacaine
caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine |
|
Active Comparator: Group LIA
Group LIA (Local Infiltration After-control group) will receive local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site at the conclusion of surgery but before emergence from anesthesia.
|
Drug: Ropivacaine
local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site |
- Usage of Pain Medications [ Time Frame: Over 24 hours ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 2 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 2 years or younger.
- Weight 33 kg or less.
- Scheduled for elective inguinal herniorrhaphy or orchiopexy.
- American Society of Anesthesiologists Class 1, 2 or 3.
Exclusion Criteria:
- Age over 2 years.
- Weight over 33 kg.
- Allergy to ropivacaine.
- Usual contraindications to caudal anesthesia (patient refusal, skeletal or spinal cord anomaly, coagulopathy, infection at insertion site, ongoing bacteremia)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00616577
| United States, California | |
| Loma Linda University Medical Center | |
| Loma Linda, California, United States, 92354 | |
| Principal Investigator: | Charles Lee, M.D. | Loma Linda University Medical Center |
| Responsible Party: | Loma Linda University |
| ClinicalTrials.gov Identifier: | NCT00616577 |
| Other Study ID Numbers: |
57235 |
| First Posted: | February 15, 2008 Key Record Dates |
| Results First Posted: | April 8, 2015 |
| Last Update Posted: | April 25, 2019 |
| Last Verified: | April 2019 |
|
Caudal Epidural Ropivacaine |
|
Ropivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |

